SCHEMBL1383479

SCHEMBL1383479

Cc1cccc(NC(=O)Nc2ccc(-c3cccc4noc(N)c34)cc2)c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 19/20 0.70
FLT3 P36888 18/20 0.70
KIT P10721 9/20 0.70
PDGFRB P09619 5/20 0.70
CSF1R P07333 6/20 0.61
FLT1 P17948 6/20 0.61
LCK P06239 5/20 0.61
FLT4 P35916 5/20 0.61
RPS6KB1 P23443 5/20 0.61
AURKB Q96GD4 5/20 0.61
ROCK2 O75116 4/20 0.61
RET P07949 4/20 0.61
FGFR1 P11362 4/20 0.61
HIPK4 Q8NE63 4/20 0.61
CLK4 Q9HAZ1 4/20 0.61
AURKA O14965 3/20 0.61
MAP4K4 O95819 3/20 0.61
FRK P42685 3/20 0.61
CLK2 P49760 3/20 0.61
CSNK1G2 P78368 3/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1382188 0.92 KDR (0.70) KDRFLT3KITPDGFRBCSF1R
SCHEMBL4737316 0.91 KDR (0.68) KDRFLT3KITPDGFRBCSF1R
SCHEMBL1383101 0.89 KDR (0.67) KDRFLT3KITPDGFRBCSF1R
SCHEMBL1383493 0.87 KDR (0.72) KDRFLT3KITPDGFRBCSF1R
SCHEMBL5253141 0.87 KDR (0.70) KDRFLT3KITPDGFRBCSF1R
SCHEMBL4736063 0.87 KDR (0.70) KDRFLT3KITPDGFRBCSF1R
SCHEMBL4740182 0.86 KDR (0.72) KDRFLT3KITPDGFRBCSF1R
SCHEMBL4738714 0.86 KDR (0.63) KDRFLT3KITPDGFRBAURKB
SCHEMBL1380731 0.86 KDR (0.72) KDRFLT3KITPDGFRBCSF1R
SCHEMBL4740220 0.86 KDR (0.72) KDRFLT3KITPDGFRBCSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4810427-B2 2011-11-09 JP claimed
WO-2008080110-A1 METHODS FOR TREATING MACULAR EDEMA AND PATHOLOGIC OCULAR ANGIOGENESIS USING A NEUROPROTECTIVE AGENT AND A RECEPTOR TYROSINE KINASE INHIBITOR ALCON, INC. (CH) 2008-07-03 WO claimed
EP-1850839-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON INC. (CH) 2007-11-07 EP claimed
WO-2006091801-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON, INC. (CH) 2006-08-31 WO claimed
EP-1638941-A1 INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2006-03-29 EP claimed
WO-2004113304-A1 INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2004-12-29 WO claimed
EP-1850839-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON INC. (CH) 2007-11-07 EP disclosed
WO-2006091801-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON, INC. (CH) 2006-08-31 WO disclosed